{"id":"ceftazidime-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ceftazidime works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-negative and gram-positive bacteria, with particular efficacy against Pseudomonas aeruginosa. The drug is bactericidal and is commonly used to treat serious infections in hospitalized patients.","oneSentence":"Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:17:31.997Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections including pneumonia, meningitis, and intra-abdominal infections"},{"name":"Pseudomonas aeruginosa infections"},{"name":"Febrile neutropenia in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT07327619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-22","conditions":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia","enrollment":420},{"nctId":"NCT06864585","phase":"","title":"A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-03-15","conditions":"Infectious Diseases","enrollment":59},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT06051513","phase":"NA","title":"Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae Infection","status":"RECRUITING","sponsor":"Southeast University, China","startDate":"2023-11-27","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection","enrollment":404},{"nctId":"NCT06818565","phase":"NA","title":"Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-10","conditions":"Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT04192994","phase":"NA","title":"Evaluation do Early Pars Plana Vitrectomy in Acute Endophthalmitis","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2019-01-01","conditions":"Endophthalmitis","enrollment":25},{"nctId":"NCT04927312","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of PF-06947386 in Japanese Adult Patients With Complicated Intra-abdominal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-10-01","conditions":"Complicated Intra-abdominal Infection","enrollment":60},{"nctId":"NCT04035369","phase":"NA","title":"Endophthalmitis Post Intravitreal Injections","status":"UNKNOWN","sponsor":"Unity Health Toronto","startDate":"2020-03-01","conditions":"Endophthalmitis","enrollment":310},{"nctId":"NCT04402359","phase":"","title":"Usage of Meropenem/Gentamicin Versus Ceftazidime/Avibactam in ARDS","status":"COMPLETED","sponsor":"King Abdul Aziz Specialist Hospital","startDate":"2018-07-05","conditions":"Ventilator Associated Pneumonia","enrollment":200},{"nctId":"NCT04187755","phase":"PHASE4","title":"Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever","status":"COMPLETED","sponsor":"Indonesia University","startDate":"2019-03-01","conditions":"Neutropenia, Febrile, Leukemia, Pediatric Cancer","enrollment":72},{"nctId":"NCT01601093","phase":"PHASE2","title":"Study on Ceftazidime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection","status":"SUSPENDED","sponsor":"Xiangbei Welman Pharmaceutical Co., Ltd","startDate":"2011-11","conditions":"Respiratory Tract Infections, Urinary Tract Infections","enrollment":288},{"nctId":"NCT00360607","phase":"PHASE4","title":"A Comparative Phase IV Study Evaluating Efficacy & Safety Of Magnex(Cefoperazone-Sulbactam) In Intraabdominal Infections","status":"COMPLETED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Infection","enrollment":307},{"nctId":"NCT00173901","phase":"PHASE4","title":"Adverse Drug Reactions of Different Brands of Ceftazidime Injection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2001-03","conditions":"Infection","enrollment":536}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"CARDIO-RESPIRATORY ARREST"},{"count":2,"reaction":"CLOSTRIDIUM TEST POSITIVE"},{"count":2,"reaction":"FUNGAL INFECTION"},{"count":2,"reaction":"HEART RATE INCREASED"},{"count":2,"reaction":"PNEUMONIA"},{"count":2,"reaction":"RESPIRATORY DISTRESS"},{"count":1,"reaction":"ALTERED STATE OF CONSCIOUSNESS"},{"count":1,"reaction":"ARRHYTHMIA"},{"count":1,"reaction":"BLOOD CULTURE POSITIVE"},{"count":1,"reaction":"BLOOD PRESSURE DECREASED"}],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Ceftazidime Injection","genericName":"Ceftazidime Injection","companyName":"Murdoch Childrens Research Institute","companyId":"murdoch-childrens-research-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ceftazidime is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections including pneumonia, meningitis, and intra-abdominal infections, Pseudomonas aeruginosa infections, Febrile neutropenia in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}